STING1 and small cell lung carcinoma: In the SCLC-specific phase Ib trial NCT04564027, the RAD51 inhibitor CYT-0851 achieved a 38% disease control rate, with matched biopsies revealing a STING-dependent 6.8-fold increase in CXCL10 (p=0.02), directly linking DDR inhibition to immune activation (58).